Managing hyperkalemia caused by inhibitors of the renin-angiotensinaldosterone system, N Engl J Med, vol.351, issue.6, pp.585-92, 2004. ,
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC), Eur J Heart Fail, 2016. ,
ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, J Am Coll Cardiol, 2016. ,
Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments, Eur Heart J Suppl, vol.21, pp.55-60, 2019. ,
Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes, Am J Nephrol, vol.46, issue.3, pp.213-221, 2017. ,
Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data, Eur Heart J, 2016. ,
Serum potassium levels and mortality in acute myocardial infarction, JAMA, vol.2012, issue.2, pp.157-64 ,
Serum potassium in patients with chronic heart failure: once we make a U-turn where should we go?, Eur Heart J, vol.2017, issue.38, pp.2897-2899 ,
, Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis
, Eur Heart J, 2018.
Association of hypo-and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race, Potassium Fluctuations Are Associated With Inhospital Mortality From Acute Myocardial Infarction. Soroka Acute Myocardial Infarction II, vol.2012, pp.709-717, 2018. ,
Potassium homeostasis in health and disease: A scientific workshop cosponsored by the National Kidney Foundation and the American Society of Hypertension, J Am Soc Hypertens, vol.2017, issue.12, pp.783-800 ,
Angiotensin-neprilysin inhibition versus enalapril in heart failure, N Engl J Med, vol.371, issue.11, pp.993-1004, 2014. ,
Atrial natriuretic factor inhibits ACTH stimulated aldosterone, but not cortisol, secretion in man, Eur J Clin Pharmacol, vol.35, issue.4, pp.409-421, 1988. ,
Atrial natriuretic peptide inhibits the aldosterone response to angiotensin II in man, Clin Sci, vol.70, issue.5, pp.507-519, 1986. ,
Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis, 2001. ,
Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies, Jama, vol.2019, issue.6, pp.602-603 ,
Associations of serum potassium levels with mortality in chronic heart failure patients, Eur Heart J, vol.2017, issue.38, pp.2890-2896 ,
Long-Term Potassium Monitoring and Dynamics in Heart Failure and Risk of Mortality, Circulation, vol.2018, issue.13, pp.1320-1330 ,
Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction, JACC Heart Fail, vol.7, issue.1, pp.65-76, 2019. ,
URL : https://hal.archives-ouvertes.fr/hal-02510424
Abnormalities of Potassium in Heart Failure, JACC, 2020. ,
Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry, Eur J Heart Fail, 2020. ,
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry, Prog Cardiovasc Dis, vol.24, issue.5, pp.387-418, 1966. ,
What is the optimal serum potassium level in cardiovascular patients?, J Am Coll Cardiol, vol.43, issue.2, pp.155-61, 2004. ,
Electrophysiology of Hypokalemia and Hyperkalemia, Circ Arrhythm Electrophysiol, vol.10, issue.3, 2017. ,
Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia, Eur J Heart Fail, vol.19, issue.6, pp.792-799, 2017. ,
Geographic variations in the PARADIGM-HF heart failure trial, Eur Heart J, vol.37, issue.41, pp.3167-3174, 2016. ,
Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials, Lancet, vol.2020, pp.121-128, 10244. ,
URL : https://hal.archives-ouvertes.fr/hal-02863402
Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial, JAMA Cardiol, vol.2017, issue.1, pp.79-85 ,
, BNP in AF+, vol.3019, p.2131, 1561.
2424) <0.001 NYHA functional class, n. (%) I 6 (3.7%), vol.747, p.306 ,
, Hypertension
, , p.54
, , p.60
, , p.119
, , p.61
, Prior use of ACEi, n. (%), p.115
, , p.51
, , p.141
%) 50 (30.5%) ,
, , p.154
, , p.75
, , p.18
, Sacubitril/Valsartan, vol.84
, Legend: eGFR, estimated glomerular filtration rate
,
,
, ACEi, angiotensin-converting enzyme inhibitor
,
, MRA, mineralocorticoid receptor antagonist
, ICD, intra-cardiac defibrillator; CRT, cardiac resynchronization therapy
,